Jun 2026 (Q2 FY26) — Aug 13, 2026
Dare Bioscience Q2 FY26 — Transition to Commercial Execution Underway
Read the full callDare Bioscience (DARE) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Dare Bioscience earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.19 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. | |
| Operating margin | -1582.5 | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. | |
| Net profit | -3.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.74 +1.37% · +$0.01
Performance −64.1% 1Y
1Y: $2.06 on 14 Oct 2025 → $0.74. High $3.27 (5 May 2026), low $0.71 (3 Sept 2026).
- Previous close
- $0.73
- 52-week range
- $0.71 – $3.27
- One year
- −63.90%
Overview
- Symbol
- DARE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Dare Bioscience earnings calls (DARE)
Financials
What the filings say
Net profit, year on year: +26% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | — | 0 | — | 0 | 1 | 0 | 0 |
| Operating profit | -5 | -5 | -5 | -4 | -4 | -1 | -3 | -3 |
| Operating margin | −11228.7% | — | −18016.8% | — | −162340.8% | −143.7% | −1967.1% | −1582.5% |
| Net profit | -5 | -6 | -4 | -4 | -4 | -1 | -3 | -3 |
| EPS ($ per share) | -0.55 | — | -0.50 | -0.45 | -0.28 | — | -0.21 | -0.20 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -29 | -44 | -71 | -110 | -141 | -171 | -175 | -189 |
| Total liabilities | 1 | 7 | 9 | 17 | 33 | 26 | 28 | 30 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Total assets | 8 | 7 | 8 | 56 | 44 | 21 | 22 | 32 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10 | -13 | -25 | -29 | -18 | -39 | 5 | -10 |
| Cash from investing | -1 | 6 | -0 | -0 | -0 | -1 | -1 | -0 |
| Cash from financing | 10 | 5 | 25 | 76 | 1 | 16 | 0 | 19 |
| Net cash flow | -1 | -2 | -0 | 47 | -17 | -24 | 5 | 9 |
| Capital expenditure | -0 | 0 | -0 | -0 | -0 | -1 | -1 | -0 |
| Free cash flow | -10 | -13 | -25 | -29 | -18 | -39 | 5 | -10 |
Insider filings
5 filings, all on Jun 30, 2026.
Open market
decisions to buy or sellNobody bought or sold DARE on the open market in this window. The filings below are 5 awards.
Compensation
not trading decisions- 5
- Award — granted as compensation
Latest filings (5)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Grossman Jessica D. Director | Award | 26,066 | $0 |
| Jun 30, 2026 | Steele Robin Joan Director | Award | 26,540 | $0 |
| Jun 30, 2026 | RASTETTER WILLIAM H Director | Award | 38,862 | $0 |
| Jun 30, 2026 | Matz Gregory W Director | Award | 30,805 | $0 |
| Jun 30, 2026 | Kelley Susan L. Director | Award | 23,696 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Dare Bioscience, Inc.
Free account. Everything above stays public.
Write why you follow Dare Bioscience, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading